Revvity, Inc. (RVTY) Barclays 28th Annual Global Healthcare Conference March 10, 2026 10:30 AM EDT
Company Participants
Prahlad Singh – CEO, President & Director
Conference Call Participants
Luke Sergott – Barclays Bank PLC, Research Division
Presentation
Luke Sergott
Barclays Bank PLC, Research Division
Good morning, everybody. I’m Luke Sergott. I cover life science tools and diagnostics from Barclays. With me, I have Prahlad Singh, CEO of Revvity, 2 Vs in Revvity. And we have Steve Willoughby from IR here as well.
Question-and-Answer Session
Luke Sergott
Barclays Bank PLC, Research Division
So let’s start off, and we were just kind of talking about it, like you never got credit for Signals before. And now all of a sudden, with [ Claude ] updates, now it’s like a huge issue with you guys. And you have significant launches across the platform. If you can kind of just walk us through like a 1-on-1 of what’s in your Signals business or just — and also with the new launches.
But talk about the customers that you guys serve, the lumpiness — not the lumpiness, the stickiness there, the data access, like what you’re actually doing across that platform and why you feel like AI is the thread of it taking share versus the reality versus the fear?
Prahlad Singh
CEO, President & Director
Yes. Good morning, Luke. It’s always good to be here. To start with, the Signals is a deeply embedded scientific platform where research is done today. AI is not a net disruptor, but an accelerator for the Signals platform. And I think you’ve heard us say that there could not be a bigger disconnect from what the external perception is of what the impact of AI is versus our internal conclusion and anticipation of how AI could help enhance and accelerate the signals business.
